1334602-75-3

Basic information

• Product Name: 4-(4-methoxybenzyloxy)-7-bromoquinazoline
• Synonyms: 4-(4-methoxybenzyloxy)-7-bromoquinazoline
• CAS NO: 1334602-75-3
• Molecular Weight: 345.195
• Mol File: 1334602-75-3.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: 4-(4-methoxybenzyloxy)-7-bromoquinazoline(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(4-methoxybenzyloxy)-7-bromoquinazoline(1334602-75-3)
• EPA Substance Registry System: 4-(4-methoxybenzyloxy)-7-bromoquinazoline(1334602-75-3)

Safety Data

• Hazardous Substances Data: 1334602-75-3(Hazardous Substances Data)

Upstream product

• 194851-16-6 7-bromo-4-hydroxyquinazoline 
• 824-94-2 p-methoxybenzyl chloride 
• 573675-55-5 7-bromo-4-chloro-quinazoline 
• 105-13-5 4-Methoxybenzyl alcohol 
• 194851-16-6 7-bromoquinazolin-4(3H)-one 
• 20776-50-5 2-amino-4-bromobenzoic acid 

Downstream Products

• 1334602-74-2 4-(4-chloroquinazolin-7-yl)morpholine 
• 1334600-89-3 7-morpholin-4-yl-4-((S)-3-phenyl-piperidin-1-yl)-quinazoline 
• 1334602-76-4 4-(4-methoxybenzyloxy)-7-morpholin-4-yl-quinazoline 

Relevant articles and documents

Quinazoline DNA-PK (deoxyribonucleic acid-polyketide) inhibitor

The invention belongs to the technical field of medicines, and particularly relates to quinazoline DNAPK inhibitor compounds, pharmaceutically acceptable salts or isomers thereof, pharmaceutical compositions and preparations containing the compounds, the pharmaceutically acceptable salts or the isomers thereof, and a method for preparing the compounds, the pharmaceutically acceptable salts or theisomers thereof, as well as uses of the compounds, pharmaceutically acceptable salts thereof, or isomers thereof.

Morpholinylquinazolines

The invention relates to compounds of the formulae (I), (II) and (III) in which R1, R2, R3, R4, Y, W1, W2, L, A, Alk, Cyc, Ar, Het1, Het2, Hal and n have the meaning indicated in claim 1, and/or physiologically acceptable salts, tautomers and stereo-isomers thereof, including mixtures thereof in all ratios. The compounds of the formula (I) can be used for the inhibition of serine/threonine protein kinases and for the sensitisation of cancer cells to anticancer agents and/or ionising radiation. The invention also relates to the use of the compounds of the formula (I) in the prophylaxis, therapy or progress control of cancer, tumours, metastases or angiogenesis disorders, in combination with radiotherapy and/or an anticancer agent. The invention furthermore relates to a process for the preparation of the compounds of the formula (I) by reaction of compounds of the formulae (II) and (III) and optionally conversion of a base or acid of the compounds of the formula (I) into one of their salts.